Form 4: Voyager Therapeutics Director Granted Stock Options

Voyager Therapeutics, Inc. reports a Form 4 filing detailing the grant of stock options to Director Grace Colon.

Summary

• Grace Colon, a Director at Voyager Therapeutics, Inc., was granted 30,000 stock options on June 9, 2026.
• The stock options have an exercise price of $3.43 per share.
• These options are issued under the company's 2025 Stock Incentive Plan and are part of the director compensation policy.
• The options vest one year from the grant date or on the date of the next annual stockholder meeting, whichever comes first, provided the director continues to serve.
• The filing also includes a Power of Attorney document, appointing individuals to act on behalf of Grace Colon for SEC filings.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it pertains to standard director compensation and does not offer new financial or strategic information about the company's operations or outlook.

Positives

• Director compensation through stock options aligns the interests of management with shareholders.
• The grant of options suggests confidence in the company's future performance, as the value of the options increases with the stock price.
• The vesting schedule encourages continued service and commitment from the director.

Negatives

• The filing does not provide details on the company's financial performance or operational updates, focusing solely on a director's compensation.
• The exercise price of $3.43 indicates that the stock price needs to increase significantly for these options to be profitable.

Risks

• The value of the stock options is subject to market volatility and the company's future stock performance.
• If the company's stock price does not exceed the exercise price of $3.43, the options will not be financially beneficial.
• The vesting is contingent on continued service, meaning the director could forfeit unvested options if they leave the company.

Future Outlook

The stock options granted to Grace Colon vest over a period of one year or until the next annual meeting, contingent on her continued service as a director. The value of these options is directly tied to the future performance of Voyager Therapeutics' stock price.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aiming to attract and retain experienced leadership while aligning their financial interests with long-term shareholder value.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Grace Colon is a related party transaction, as she is a director of Voyager Therapeutics, Inc.

Stakeholder Impact

• Shareholders: The grant of options does not immediately impact share price but represents potential future dilution if exercised. It aligns director incentives with stock performance.
• Employees: No direct impact, but standard compensation practices can influence overall company culture and talent retention.
• Management: Reinforces standard compensation structures for board members.

Next Steps

• Grace Colon will continue to serve as a Director of Voyager Therapeutics, Inc.
• The stock options will vest according to the schedule outlined in the filing.
• Voyager Therapeutics, Inc. will continue to operate under its 2025 Stock Incentive Plan.

Key Dates

Keywords

Voyager Therapeutics, VYGR, Form 4, Stock Options, Director Compensation, SEC Filing, Insider Trading, Equity Incentive Plan